Ophthalmology. Retina最新文献

{"title":"Bilateral Optic Disc Edema and Retinal Flecks due to Vitamin A Deficiency.","authors":"Aidan A Dmitriev, Meghal Gagrani","doi":"10.1016/j.oret.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.oret.2025.03.009","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Nematode.","authors":"Vasco Lobo, Paulo Rosa, Inês Leal","doi":"10.1016/j.oret.2025.02.021","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.021","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Effects of Anti-VEGF Therapy versus Panretinal Photocoagulation on Retinal Vessel Caliber in Eyes with Proliferative Diabetic Retinopathy.","authors":"Steven Shen, Kristin Josic, Jeong W Pak, Stacy M Meuer, Michele Melia, Amitha Domalpally, Jennifer K Sun, Barbara Blodi","doi":"10.1016/j.oret.2025.03.027","DOIUrl":"https://doi.org/10.1016/j.oret.2025.03.027","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the long-term effects of ranibizumab compared with panretinal photocoagulation (PRP) on retinal vasculature in eyes with proliferative diabetic retinopathy (PDR).</p><p><strong>Design: </strong>Post hoc analysis of DRCR Retina Network Protocol S randomized clinical trial.</p><p><strong>Participants: </strong>Adults with type 1 or 2 diabetes and PDR in at least 1 eye.</p><p><strong>Methods: </strong>Integrative Vessel Analysis software was used to measure central retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE) of vessels at 1 disc diameter from the optic nerve edge on fundus photographs at baseline, 2 and 5 years for study eyes randomized to ranibizumab or PRP treatment for PDR. Changes in CRAE and CRVE were analyzed using mixed linear regression models with multivariable adjustments.</p><p><strong>Main outcome measures: </strong>Mean change in CRAE and CRVE from baseline to 2 and 5 years.</p><p><strong>Results: </strong>Data from 107 eyes (90 participants) in the ranibizumab (n = 48) and PRP group (n = 59) were analyzed. For the ranibizumab versus PRP groups, CRAE decreased by a mean of 2 versus 12 μm at 2 years (mean difference, 10 μm; 95% confidence interval [CI], 4-16; P = 0.003); and 9 versus 13 μm at 5 years (mean difference, 4 μm; 95% CI, -2 to 10; P = 0.22). Central retinal venular equivalent decreased by 14 versus 19 μm at 2 years (mean difference, 4 μm; 95% CI, -3 to 11; P = 0.26) and 18 versus 28 μm at 5 years (mean difference, 11 μm; 95% CI, 3-19; P = 0.01).</p><p><strong>Conclusions: </strong>In patients with PDR, CRAE and CRVE decreased in both the ranibizumab and PRP groups at 5 years, but the rates of change before and after 2 years may be different. In this subset of eyes from Protocol S, the greater reduction in CRAE in the PRP group was statistically significant at 2 years but not at 5 years. For CRVE, the PRP group decreased more than the ranibizumab group, but the difference was statistically significant at 5 but not 2 years. Future research may investigate the underlying causes for retinal arteriolar and venular narrowing after treatment for PDR, and the possibility of an anatomic correlation with visual field loss.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Reduplications in Aggressive Retinopathy of Prematurity.","authors":"Shakha, Parijat Chandra","doi":"10.1016/j.oret.2025.02.020","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic Spectrum of Benign Lobular Inner Nuclear Layer Proliferations: A Multicenter Analysis and Review of the Literature.","authors":"Michael Javaheri, Christian J Sanfilippo, Sundeep K Kasi, Rachel Chen, Jose M Ruiz-Moreno, Carol L Shields, David A Saperstein, Amy Yuan, Brandon J Lujan, Heinrich Heimann, Rutika Dodeja, Chris Bergstrom, Özge Yanık, Jesse L Berry, Aaron Nagiel","doi":"10.1016/j.oret.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.oret.2025.04.004","url":null,"abstract":"<p><strong>Objective: </strong>To report the clinical and imaging features of 8 new and 9 published cases with benign lobular inner nuclear layer proliferations (BLIPs).</p><p><strong>Design: </strong>Retrospective case series and literature review.</p><p><strong>Participants: </strong>Eight previously unreported patients from 7 institutions internationally and 10 reported cases in the literature.</p><p><strong>Methods: </strong>Retrospective analysis of clinical and imaging features of BLIPs including systematic review of published cases using relevant terms.</p><p><strong>Main outcomes and measures: </strong>Description of multimodal imaging and systemic findings in 17 patients with BLIPs.</p><p><strong>Results: </strong>Eight new cases and 10 previously published cases with BLIPs were reviewed for clinical features, systemic associations, and imaging findings. The tumors were mostly unilateral (16 of 18 cases; 88%), associated with ipsilateral grouped congenital hypertrophy of the retinal pigment epithelium lesions (16 of 20 eyes; 80%), and located posterior to the equator. In all eyes, the tumors were multifocal, and many had curvilinear extensions that extended beyond the central tumor lobules. OCT demonstrated these lesions to be centered within the inner nuclear layer at the border of the inner plexiform layer with no invasion of adjacent layers. Visual acuity was normal (mean: 0.024 logarithm of the minimum angle of resolution; range: -0.01 to 0.3) in all cases, and most patients were asymptomatic. No plausible genetic or systemic associations could be identified.</p><p><strong>Conclusions: </strong>This expanded series of BLIPs further refines the clinical characteristics and imaging findings associated with this newly described benign retinal tumor.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pachyvitelliform Maculopathy: Clinical Features and Natural History.","authors":"Maria Vittoria Cicinelli, Lorenzo Bianco, Prithvi Ramtohul, Lorenzo Caminada, Chiara Giuffré, Maria Pia De Carlo, Matteo Oliari, Ugo Introini, Francesco Bandello","doi":"10.1016/j.oret.2025.04.003","DOIUrl":"10.1016/j.oret.2025.04.003","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the prevalence, clinical features, associated factors, and natural history of pachyvitelliform maculopathy (PVM) within the pachychoroid disease spectrum (PDS).</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Subjects: </strong>Patients affected with PDS were evaluated at a single retina referral center between 2006 and 2024.</p><p><strong>Methods: </strong>Demographics, medical history, and imaging features were reviewed. Pachyvitelliform maculopathy was diagnosed based on the presence of acquired vitelliform lesions (AVLs), identified as hyperreflective material above the retinal pigment epithelium (RPE) band on spectral-domain OCT and corresponding hyperautofluorescence on fundus autofluorescence imaging. Acquired vitelliform lesions were tracked longitudinally using serial OCT.</p><p><strong>Main outcome measures: </strong>Factors associated with AVL development were assessed using multivariable logistic regression. The hazard of AVL persistence was evaluated with Cox regression. Complication rates were reported as absolute prevalence, and visual acuity (VA) changes were analyzed longitudinally using repeated measures modeling.</p><p><strong>Results: </strong>Among 986 eyes with PDS, 48 (5%) demonstrated PVM. Key associations included recurrent fluid episodes (odds ratio [OR], 2.87; P = 0.002), thinner outer nuclear layer (OR, 0.89; P = 0.03), and choroidal folds (OR, 3.39; P = 0.002). Subfoveal AVLs were most common, observed in 79% of cases. Acquired vitelliform lesion typically developed at the apex of the subfoveal serous cavity or along its lateral edges, beginning with ellipsoid zone thickening, followed by suspended hyperreflective material settling onto the RPE and forming deposits. These deposits consolidated over time, appearing as \"pachydrusen\" or resembling the \"double-layer sign.\" Indocyanine green angiography highlighted localized choroidal vascular hyperpermeability at AVL sites. Subfoveal lesions, a thicker Haller's layer, and increased peripapillary choroidal thickness were associated with reduced AVL resolution (all P < 0.05). Lesion turnover was slow (median 50 months); complications, including neovascularization (6%) and atrophy (4%), were rare, and VA remained stable over 7 years (P = 0.07).</p><p><strong>Conclusions: </strong>Pachyvitelliform maculopathy represents a distinct phenotype within PDS, characterized by prolonged lesion persistence, recurrent fluid, and a relatively benign visual prognosis. Structural choroidal changes and RPE dysfunction drive lesion formation and progression.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Next Frontier for Macular Hole Surgery: Estimating Functional Success","authors":"Michael A. Klufas MD","doi":"10.1016/j.oret.2024.12.020","DOIUrl":"10.1016/j.oret.2024.12.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages 303-304"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral Dual Congenital Retinal Macrovessels","authors":"Tarannum Mansoori MS ,&nbsp;Satish Gooty Agraharam MS ,&nbsp;Swetha Nasani DO","doi":"10.1016/j.oret.2024.08.010","DOIUrl":"10.1016/j.oret.2024.08.010","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Page e33"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accessory Fovea in Human Eye","authors":"Ryan Zubricky MD,&nbsp;Tamara Vrabec MD","doi":"10.1016/j.oret.2024.08.012","DOIUrl":"10.1016/j.oret.2024.08.012","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Page e34"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration","authors":"Jan Hamouz MD ,&nbsp;Agnieszka Nowosielska MD ,&nbsp;Anna Święch-Zubilewicz MD ,&nbsp;Santiago Abengoechea MD ,&nbsp;Kristine Baumane MD ,&nbsp;Attila Vajas MD ,&nbsp;Małgorzata Siewierska MD ,&nbsp;Milan Veselovsky MD ,&nbsp;Miroslav Veith MD ,&nbsp;Ágnes Kerényi MD ,&nbsp;Shobhana Mange MD ,&nbsp;Krishnapada Baidya MD ,&nbsp;Guna Laganovska MD ,&nbsp;Ignasi Jürgens MD ,&nbsp;András Papp MD ,&nbsp;Jignesh Gosai MD ,&nbsp;Jana Štefanickova MD ,&nbsp;Mei Han MD ,&nbsp;Piotr Fryczkowski MD ,&nbsp;Dominik Zalewski MD ,&nbsp;Wenbin Wei MD","doi":"10.1016/j.oret.2024.10.001","DOIUrl":"10.1016/j.oret.2024.10.001","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to demonstrate the clinical equivalence of biosimilar QL1205 and reference ranibizumab, Lucentis, in patients with neovascular age-related macular degeneration (nAMD).</div></div><div><h3>Design</h3><div>This was a multicenter, double-masked, randomized, controlled phase III trial.</div></div><div><h3>Participants</h3><div>Treatment-naive patients with active nAMD were randomly assigned to receive QL1205 or reference ranibizumab.</div></div><div><h3>Methods</h3><div>Patients received intravitreal injection of QL1205 or reference ranibizumab at a dose of 0.5 mg in the study eye once every 4 weeks for 48 weeks.</div></div><div><h3>Main Outcome Measures</h3><div>The primary end point was change in best-corrected visual acuity (BCVA) by ETDRS letters at week 8 compared with baseline level. Biosimilarity of QL1205 to reference ranibizumab was assessed with an equivalence range for the difference in BCVA letters between −3.49 and +3.49.</div></div><div><h3>Results</h3><div>Between June 27, 2019 and June 8, 2021, 616 patients were randomized to the QL1205 group (n = 308) and the reference ranibizumab group (n = 308). The mean improvement of BCVA was +6.3 ± 9.13 ETDRS letters in the QL1205 group and +7.3 ± 8.82 ETDRS letters in the reference ranibizumab group at week 8. Both the 90% confidence interval (CI, −2.23 to 0.13) and 95% CI (−2.46 to 0.36) of the difference between the 2 treatment groups (<em>P</em> = 0.1434) were within the predefined equivalence range. Safety profiles were manageable in both groups.</div></div><div><h3>Conclusions</h3><div>QL1205 was biosimilar to reference ranibizumab regarding clinical efficacy, ocular and systemic safety, as well as immunogenicity and pharmacokinetics profiles in the treatment of patients with nAMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages 343-351"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}